Thermo Fisher Scientific Inc. , a global leader in life sciences solutions and analytical instruments, announced the launch of two new state-of-the-art mass spectrometers on June 2: the Thermo Scientific Orbitrap Astral Zoom Mass Spectrometer/MS and the Thermo Scientific Orbitrap Excedion Pro Mass Spectrometer/MS. The unveiling took place at the American Society for Mass Spectrometry (ASMS) annual conference, held from June 1 to 5 in Baltimore, Maryland.
These latest additions to Thermo Fisher’s Orbitrap platform are designed to elevate analytical precision and speed, enabling researchers to explore complex biological systems with greater depth and accuracy. The advanced capabilities are expected to contribute significantly to breakthroughs in precision medicine, particularly in understanding complex diseases such as Alzheimer’s and cancer.
The Orbitrap Astral Zoom MS builds on the success of its award-winning predecessor, the Orbitrap Astral. The new system offers notable performance enhancements, including 35% faster scanning speeds, 40% greater throughput, and a 50% increase in multiplexing capabilities. These improvements translate into heightened sensitivity and expanded experimental flexibility, empowering scientists to conduct more comprehensive and efficient analyses.
Thermo Fisher Scientific’s diverse portfolio spans life sciences, analytical instruments, specialty diagnostics, laboratory products, and biopharma services across global markets. The company continues to play a critical role in supporting scientific research, clinical diagnostics, and drug development through its innovative solutions.
While Thermo Fisher Scientific remains a strong contender for investors seeking exposure to the life sciences and healthcare sectors, some analysts suggest that certain AI-focused stocks may currently offer even more attractive short-term growth opportunities with potentially lower downside risks. Investors looking to capitalize on emerging trends, including Trump-era tariffs and the broader onshoring movement, may find particularly undervalued AI stocks worth exploring in the near term.